Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of STAAR Surgical Company (STAA) Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) securities between February 26, 2020 and August 10, 2020, inclusive (the “Class Period”). STAAR investors have until October 19, 2020 to file a lead plaintiff motion.

If you suffered a loss on your STAAR investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/staar-surgical-company/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [e-mail] to learn more about your rights.

On August 11, 2020, J Capital published a report, claiming the Company has overstated its sales in China by at least one-third (or $21.6 million), "meaning all of the company's $14 mln in 2019 profit is fake." Citing over 75 interviews with former employees, site visits to China and Switzerland, as well as extensive review of public documents, the report concludes that STAAR reports fake sales revenues by overstating sales and then marking up actual marketing costs to hide "phantom" revenue. According to the report, the financial statements for STAAR’s largest Chinese client indicate that it bought only about half as many lenses as the Company reports.

On this news, the Company’s share price fell $3.17, or over 6%, to close at $48.25 per share on August 11, 2020, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that STAAR is the subject of a report by investment analyst J Capital titled, "STARR Surgical, Less Than Meets the Eye." The report alleges that the Company has overstated its sales in China by at least one-third, "meaning all of the Company's $14 mln in 2019 profit is fake." The report, based on extensive interviews and research, states that the Company reports fake sales numbers and then marks up marketing costs in a scheme to hide "phantom" revenue.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased STAAR securities during the Class Period, you may move the Court no later than October 19, 2020 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [e-mail], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.